毒性适应性列表设计:在瘤学中进行第一阶段药物组合试验的实用设计
Massimiliano Russo1, Francesco Mariani2, James M Cleary3,4
1Department of Statistics, The Ohio State University, Columbus, OH.
我们为瘤学试验开发了一种新的毒性适应性列表设计 (TALE). TALE安全地确定药物组合的最大耐受剂量 (MTD),平衡患者安全和治疗疗效.
科学领域:
- 在瘤学瘤学.
- 临床试验设计 临床试验设计
- 制药指标 (Pharmacometrics) 是一个指标.
背景情况:
- 第I期瘤学试验对于评估新药组合至关重要.
- 准确确定最大耐受剂量 (MTD) 对于患者的安全性和疗效至关重要.
- 现有的剂量确定方法在管理毒性和效率方面存在局限性.
研究的目的:
- 引入一种新的算法方法,即毒性适应性列表设计 (TALE),用于第一阶段瘤学药物组合试验.
- 为剂量升级和降级提供灵活和可实施的设计.
- 根据积累的数据,能够同时分配安全剂量组合.
主要方法:
- TALE使用预先规定的参数来定义剂量调整规则 (升级,降级,重新评估).
- 设计控制剂量探索,并限制毒性发生.
- 它允许同时将患者纳入被认为是安全的多剂量组合组.
主要成果:
- 数字研究表明,TALE在识别MTD方面具有与现有方法 (BOIN,COPULA,PINT,CRM) 相当的性能.
- 与替代设计相比,TALE有效降低了患者过量服用的风险.
- 塔尔的操作特性是强大的和可靠的.
结论:
- 塔尔的设计在患者安全和MTD识别准确性之间提供了更好的平衡.
- TALE是实用的临床实施,由一个R包和Shiny应用程序支持.
- 这种方法促进了对新瘤药物组合的安全和有效探索.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Clinical Trials: Overview
Toxic Reactions: Overview
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Therapeutic Index
Preclinical Development: Overview
Targeted Cancer Therapies
There are several types of targeted therapies against...
